14 Perspectives of Aptamers for Medical Applications
453
100. Abdelmohsen K, Gorospe M (2012) RNA-binding protein nucleolin in disease. RNA Biol
9(6):799–808. https://doi.org/10.4161/rna.19718
101. Reyes-Reyes EM, Šalipur FR, Shams M, Forsthoefel MK, Bates PJ (2015) Mechanistic studies
of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.
Mol Oncol 9(7):1392–1405. https://doi.org/10.1016/j.molonc.2015.03.012
102. Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ (2008) The nucleolin
targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.
Cancer Res 68(7):2358–2365. https://doi.org/10.1158/0008-5472.Can-07-5723
103. Laber D, Taft B, Kloecker G, Bates P, Trent J, Miller D (2006) Extended phase I study of
AS1411 in renal and non-small cell lung cancers. J Clin Oncol 24 (18_suppl):13098–13098
104. Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN Jr, Harzstark AL, Wagle
N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA (2014) A phase II
trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.
Invest New Drugs 32(1):178–187. https://doi.org/10.1007/s10637-013-0045-6
105. Vater A, Sahlmann J, Kröger N, Zöllner S, Lioznov M, Maasch C, Buchner K, Vossmeyer D,
Schwoebel F, Purschke WG, Vonhoff S, Kruschinski A, Hübel K, Humphrey M, Klussmann
S, Fliegert F (2013) Hematopoietic stem and progenitor cell mobilization in mice and humans
by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. Clin Pharmacol Ther
94(1):150–157. https://doi.org/10.1038/clpt.2013.58
106. Steurer M, Montillo M, Scarfò L, Mauro FR, Andel J, Wildner S, Trentin L, Janssens A,
Burgstaller S, Frömming A, Dümmler T, Riecke K, Baumann M, Beyer D, Vauléon S, Ghia
P, Foà R, Caligaris-Cappio F, Gobbi M (2019) Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica 104(10):2053–2060. https://doi.org/10.3324/haematol.2018.
205930
107. Arnedos M, Bihan C, Delaloge S, Andre F (2012) Triple-negative breast cancer: are we
making headway at least? Ther Adv Med Oncol 4(4):195–210. https://doi.org/10.1177/175
8834012444711
108. Camorani S, Crescenzi E, Gramanzini M, Fedele M, Zannetti A, Cerchia L (2017) Aptamermediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and
growth of triple-negative breast cancers. Sci Rep 7:46659. https://doi.org/10.1038/srep46659
109. Shu D, Li H, Shu Y, Xiong G, Carson WE 3rd, Haque F, Xu R, Guo P (2015) Systemic
delivery of Anti-miRNA for suppression of triple negative breast cancer utilizing RNA
Nanotechnology. ACS Nano 9(10):9731–9740. https://doi.org/10.1021/acsnano.5b02471
110. Kim MW, Jeong HY, Kang SJ, Jeong IH, Choi MJ, You YM, Im CS, Song IH, Lee TS, Lee JS,
Lee A, Park YS (2019) Anti-EGF receptor aptamer-guided co-delivery of anti-cancer siRNAs
and quantum dots for theranostics of triple-negative breast cancer. Theranostics 9(3):837–852.
https://doi.org/10.7150/thno.30228
111. Xue L, Maihle NJ, Yu X, Tang SC, Liu HY (2018) Synergistic targeting HER2 and EGFR
with bivalent Aptamer-siRNA chimera efficiently inhibits HER2-Positive tumor growth. Mol
Pharm 15(11):4801–4813. https://doi.org/10.1021/acs.molpharmaceut.8b00388
112. Yu X, Ghamande S, Liu H, Xue L, Zhao S, Tan W, Zhao L, Tang SC, Wu D, Korkaya
H, Maihle NJ, Liu HY (2018) Targeting EGFR/HER2/HER3 with a three-in-One AptamersiRNA chimera confers superior activity against HER2(+) breast cancer. Mol Ther Nucleic
Acids 10:317–330. https://doi.org/10.1016/j.omtn.2017.12.015
113. Xie X, Nie H, Zhou Y, Lian S, Mei H, Lu Y, Dong H, Li F, Li T, Li B, Wang J, Lin M, Wang
C, Shao J, Gao Y, Chen J, Xie F, Jia L (2019) Eliminating blood oncogenic exosomes into the
small intestine with aptamer-functionalized nanoparticles. Nat Commun 10(1):5476. https://
doi.org/10.1038/s41467-019-13316-w
114. Iaboni M, Fontanella R, Rienzo A, Capuozzo M, Nuzzo S, Santamaria G, Catuogno S,
Condorelli G, de Franciscis V, Esposito CL (2016) Targeting insulin receptor with a novel
internalizing aptamer. Mol Ther Nucl Acids 5(9):e365. https://doi.org/10.1038/mtna.2016.73
115. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and
insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr
Rev 30(6):586–623. https://doi.org/10.1210/er.2008-0047
453
100. Abdelmohsen K, Gorospe M (2012) RNA-binding protein nucleolin in disease. RNA Biol
9(6):799–808. https://doi.org/10.4161/rna.19718
101. Reyes-Reyes EM, Šalipur FR, Shams M, Forsthoefel MK, Bates PJ (2015) Mechanistic studies
of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.
Mol Oncol 9(7):1392–1405. https://doi.org/10.1016/j.molonc.2015.03.012
102. Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ (2008) The nucleolin
targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.
Cancer Res 68(7):2358–2365. https://doi.org/10.1158/0008-5472.Can-07-5723
103. Laber D, Taft B, Kloecker G, Bates P, Trent J, Miller D (2006) Extended phase I study of
AS1411 in renal and non-small cell lung cancers. J Clin Oncol 24 (18_suppl):13098–13098
104. Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN Jr, Harzstark AL, Wagle
N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA (2014) A phase II
trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.
Invest New Drugs 32(1):178–187. https://doi.org/10.1007/s10637-013-0045-6
105. Vater A, Sahlmann J, Kröger N, Zöllner S, Lioznov M, Maasch C, Buchner K, Vossmeyer D,
Schwoebel F, Purschke WG, Vonhoff S, Kruschinski A, Hübel K, Humphrey M, Klussmann
S, Fliegert F (2013) Hematopoietic stem and progenitor cell mobilization in mice and humans
by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. Clin Pharmacol Ther
94(1):150–157. https://doi.org/10.1038/clpt.2013.58
106. Steurer M, Montillo M, Scarfò L, Mauro FR, Andel J, Wildner S, Trentin L, Janssens A,
Burgstaller S, Frömming A, Dümmler T, Riecke K, Baumann M, Beyer D, Vauléon S, Ghia
P, Foà R, Caligaris-Cappio F, Gobbi M (2019) Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica 104(10):2053–2060. https://doi.org/10.3324/haematol.2018.
205930
107. Arnedos M, Bihan C, Delaloge S, Andre F (2012) Triple-negative breast cancer: are we
making headway at least? Ther Adv Med Oncol 4(4):195–210. https://doi.org/10.1177/175
8834012444711
108. Camorani S, Crescenzi E, Gramanzini M, Fedele M, Zannetti A, Cerchia L (2017) Aptamermediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and
growth of triple-negative breast cancers. Sci Rep 7:46659. https://doi.org/10.1038/srep46659
109. Shu D, Li H, Shu Y, Xiong G, Carson WE 3rd, Haque F, Xu R, Guo P (2015) Systemic
delivery of Anti-miRNA for suppression of triple negative breast cancer utilizing RNA
Nanotechnology. ACS Nano 9(10):9731–9740. https://doi.org/10.1021/acsnano.5b02471
110. Kim MW, Jeong HY, Kang SJ, Jeong IH, Choi MJ, You YM, Im CS, Song IH, Lee TS, Lee JS,
Lee A, Park YS (2019) Anti-EGF receptor aptamer-guided co-delivery of anti-cancer siRNAs
and quantum dots for theranostics of triple-negative breast cancer. Theranostics 9(3):837–852.
https://doi.org/10.7150/thno.30228
111. Xue L, Maihle NJ, Yu X, Tang SC, Liu HY (2018) Synergistic targeting HER2 and EGFR
with bivalent Aptamer-siRNA chimera efficiently inhibits HER2-Positive tumor growth. Mol
Pharm 15(11):4801–4813. https://doi.org/10.1021/acs.molpharmaceut.8b00388
112. Yu X, Ghamande S, Liu H, Xue L, Zhao S, Tan W, Zhao L, Tang SC, Wu D, Korkaya
H, Maihle NJ, Liu HY (2018) Targeting EGFR/HER2/HER3 with a three-in-One AptamersiRNA chimera confers superior activity against HER2(+) breast cancer. Mol Ther Nucleic
Acids 10:317–330. https://doi.org/10.1016/j.omtn.2017.12.015
113. Xie X, Nie H, Zhou Y, Lian S, Mei H, Lu Y, Dong H, Li F, Li T, Li B, Wang J, Lin M, Wang
C, Shao J, Gao Y, Chen J, Xie F, Jia L (2019) Eliminating blood oncogenic exosomes into the
small intestine with aptamer-functionalized nanoparticles. Nat Commun 10(1):5476. https://
doi.org/10.1038/s41467-019-13316-w
114. Iaboni M, Fontanella R, Rienzo A, Capuozzo M, Nuzzo S, Santamaria G, Catuogno S,
Condorelli G, de Franciscis V, Esposito CL (2016) Targeting insulin receptor with a novel
internalizing aptamer. Mol Ther Nucl Acids 5(9):e365. https://doi.org/10.1038/mtna.2016.73
115. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and
insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr
Rev 30(6):586–623. https://doi.org/10.1210/er.2008-0047